In conclusion, chemoimmunotherapy with GA101 and CLB is feasible in CLL patients of advanced age and with high burden of comorbidity. The treatment combination has promising activity in this group of patients that so far has been severely neglected by clinical research. IRR and neutropenia were identified as potential risks of the G-CLB regimen. As none of the stopping criteria defined for the safety run-in phase of the trial was met, the CLL11 (BO21004) trial was opened for randomization in April 2010.
The chemotherapy backbone for group B patients was similar to that reported in the FAB/LMB 96 study for the B4 arm. 3 The reduction phase consisted of low-dose cyclophosphamide, Oncovin and prednisone (COP). The two induction courses (COPADM1 þ 2) consisted of cyclophosphamide 1.5 g/m 2 per course-fractionated, vincristine, prednisone, doxorubicin and high-dose methotrexate (HDMTX) (3 g/m 2 in 3 h of infusion with intrathecal methotrexate). Patients then received two identical consolidation courses, CYM1 þ 2 (continuous-infusion cytarabine and high-dose methotrexate). Patients with o20% COP response or biopsy-proven residual disease between consolidation cycles were switched to the more intensive group C regimen as previously described. [3] [4] [5] Rituximab (375 mg/m 2 ), supplied by Genentech (San Francisco, CA, USA) through the Cancer Therapy Evaluation Program, was diluted in normal saline and infused at 0.5 mg/kg/h for the first hour of the initial infusion and then increased every 30 min per patient tolerance as we have previously described. 6 Monitoring of blood pressure, pulse, respiratory rate and temperature was done every 15 min. During induction cycles (COPADM), dose-dense rituximab was administered 48 h prior (day -2) and repeated on the day of chemotherapy administration (day 0) as described by Pfreundschuh et al. 7 During consolidation cycles (CYM), rituximab was administered just prior to chemotherapy administration (day 0). In the initial subpilot, the rituximab administration began with the second induction cycle (four total doses). In the pilot study, rituximab was given, beginning with the first induction cycle (six total doses) (Supplementary Figures 1A-D) .
A subpilot (n ¼ 7) of patients with Stage III/IV disease (and receiving only four doses of rituximab) preceded the pilot study, the purpose of which was to verify that there were no unexpected early toxic events.
Stevens-Johnson syndrome, toxic epidermal necrosis, frequency of gradeX3 stomatitis and delayed recovery beyond day þ 42 of the induction phase were events of concern in the subpilot and main pilot studies.
A separate rule for temporarily or permanently closing the subpilot was included. If a single toxic death was observed during the second cycle of the induction (COPADM2 þ rituximab) through the end of the consolidation course (CYM2 þ rituximab) among the seven subpilot patients, then the Study Committee was to review the event and determine if the study would continue forward or if it should be modified or permanently closed.
The primary objective of this study was to monitor and assess toxicity to ensure that the addition of rituximab to standard therapy would not unduly increase the rate and degree of toxic events. Two events were of particular interest, the incidence of gradeX3 stomatitis and any occurrence of a toxic death. A three-stage stopping rule was used to terminate this study if too many group B patients experienced gradeX3 stomatitis during either cycle of COPADM þ rituximab therapy (induction). A rate 448%, the observed rate in FAB/LMB 96, was considered too high.
If there was a single incidence of Stevens-Johnson syndrome or toxic epidermal necrosis among the 44 group B patients during either induction cycle, the trial was to be temporarily closed to group B patients for the review of the event. Finally, deaths were monitored and any detectable increase in the toxic death rate above the 1.2% rate observed on FAB/LMB 96 was of concern.
Analysis of event-free survival (EFS) and overall survival (OS) was performed using the Kaplan and Meier method. 5 The 95% confidence interval (CI 95 ) for the Kaplan-Meier estimates of EFS and OS was calculated using s.e.'s according to Greenwood's formula. 8 The study opened in the subpilot phase in June 2004. Seven patients were enrolled to the subpilot. After prespecified safety closure (1.25 years), the pilot study opened in September 2005. Forty-four pilot patients were enrolled through the planned study closure date in October 2006. Five pilot patients were determined to be ineligible (all prior to receiving rituximab). In addition, one eligible pilot patient was found to have central nervous system (CNS) blasts and was switched to group C and excluded from further analysis. Thus, 38 pilot and 7 subpilot patients were included.
The mean age at study entry was 11 years (range 1-23 years) and 11% of the patients were less than 4 years of age. The male:female ratio was 3.5:1. Eighty-nine percent of patients were in St Jude Stage III. Forty-eight percent of patients had elevated LDH X2 Â upper limit of institutional normal. The majority of patients had Burkitt lymphoma (56%). Diffuse large B-cell lymphoma was the second most frequent histology (22%), followed by 4 cases (9%) of mediastinal primary B-cell lymphoma. All centrally reviewed histological subtypes expressed CD20 (Supplementary Table 1 ).
There were no toxic deaths. Figure 1 details the most common recurrent non-hematological grade III/IV toxicities by cycle of therapy. There were 19 reports in five patients of serious adverse events. No serious adverse event was probably or definitely attributed to rituximab. One episode of grade III infectious colitis occurred after the second induction cycle and was attributed as possibly related to rituximab administration. There were no grade III/IV infusion reactions reported among the 256 doses of rituximab. Prespecified stopping rules for unacceptable rates of mucositis/stomatitis and Stevens-Johnson syndrome were not met. The incidence of grade III/IV mucositis during induction cycles was 11% and 9% in COPADM 1 and COPADM 2, respectively. Human antichimeric antibody analyses were performed in seven consenting patients from 6 weeks to 1 year post completion of rituximab therapy (39 samples) with no positive results.
The response rate (complete response/partial response) after completion of the two induction cycles was 75% (CI 95 30-95%) and 89% (CI 95 73-96%) in the sub-pilot and pilot patients, respectively. After the first consolidation cycle, patients were required to undergo biopsy of any residual disease and if found positive, they were switched to a more intensive group C consolidation. 4 One patient had biopsy-proven residual disease at this disease evaluation (complete response rate 98% post consolidation).
There have been three patients with reported events of recurrent disease. Two of four patients with mediastinal primary disease developed recurrent disease at 8 and 34 months, respectively, from study entry. In the remaining 41 patients, only Figure 1 . Percentage of grade III/IV non-hematological toxicities during chemoimmunotherapy cycles. Rates of grade III/IV infection, mucositis and pain, by treatment cycle. In the initial subpilot, patients did not receive rituximab during the first induction cycle (COPADM1) and therefore toxicity for this cycle is shown separately. All other cycles combine subpilot (n ¼ 7) and pilot (n ¼ 38) data.
one patient with Burkitt lymphoma developed recurrent disease at 4 months post study entry. Two deaths have occurred (both with previous recurrent disease) at 13 and 18 months from study entry, respectively. The median follow-up for the 43 patients alive at last contact is 3.5 years. The 3-year EFS among all 45 eligible patients is 93% (CI 95 79-98%), the 3-year EFS among pilot patients (six doses of rituximab) is 95% (CI 95 80-99%) (Figure 2a ) and the three-year OS among pilot patients is 95% (CI 95 83-99%) (Figure 2b) . This is the first prospective study to report the addition of targeted immunotherapy to a multiagent chemotherapy regimen in newly diagnosed children and adolescents with stage III/IV de novo mature B-NHL. Our findings demonstrate that dose-dense rituximab therapy can be safely added to chemotherapy and results in a 95% 3-year EFS. Importantly, two of the relapses occurred in patients with a mediastinal primary, which is a subgroup with a known poorer prognosis in the context of FAB/LMB therapy. 7 In our previous experience in the FAB/LMB 96 trial (with 6 h of doxorubicin infusion), the incidence of grade III and IV mucositis during COPADM1 (B 1, 2, 3, 4 arms) and COPADM2 (B 3, 4 arms) was 43% and 31%, respectively. 3 For this reason, we further reduced the doxorubicin infusion to p1 h in the current study. These safety results are in line with over a decade of use of combination chemotherapy regimens with rituximab in adult patients with B-NHL. 7, 9 Our study, however, was not powered to monitor for rare but highly morbid events such as progressive multifocal leukoencephalopathy (due to reactivation of latent John Cunningham virus) that have been described in adults treated with rituximab. 10, 11 Our outcome results demonstrate both a 3-year EFS of 95% (CI 95 80-99%) in pilot patients (six doses of rituximab) and a 3-year OS of 95% (CI 95 80-99%). In the prior FAB/LMB 96 study, which utilized the same FAB/LMB 96 chemotherapy only, the 5-year EFS in patients with stage III/IV B-NHL was 84% (CI 95 80-86%) (Figure 2c) . 3, 12 These current results are the best reported to date and only utilized 12 weeks of chemoimmunotherapy. In comparison, the 10-year progression-free survival in adults with Stage III/IV diffuse large B-cell lymphoma treated with R-CHOP (rituximab þ cyclophosphamide, adriamycin, vincristine and prednisone) is only 37%. 13 Finally, a more intriguing use of rituximab in children and adolescents with de novo mature B-NHL may be to substitute for chemotherapy, thereby potentially reducing morbidity and late effects.
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Department of Cytogenetics, University of Nebraska Medical
Center, Omaha, NE, USA; Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of a population of CD5 þ / CD23 þ mature B lymphocytes in the peripheral blood, bone marrow and lymph nodes. 1 In vivo studies have shown that a significant proportion of the leukemic clone renovates daily and that cell proliferation occurs almost exclusively in lymphoid organs. Here, an intense bi-directional crosstalk takes place between the CLL cell and surrounding non-neoplastic lymphoid and stromal elements.
2 The lymph node architecture is then molded into an anatomically defined niche, known as the proliferation center, where the antigen(s) is presented to the neoplastic cell together with a cocktail of soluble and cell-bound accessory signals. 3 The ensuing proliferation may lead to the acquisition of novel genetic lesions or to the expansion of pre-existing leukemic subclones harboring deleterious mutations. Hence, therapeutic strategies aimed at preventing localization to these growth-privileged areas may enhance efficacy of conventional chemotherapies.
Our original interest in CLL derives from the observation that CD38, an ectoenzyme and a receptor is a negative prognostic marker for CLL patients. The finding that CD38 is expressed by a subset of CLL cells characterized by a more aggressive course of the leukemia, with a shorter time to first treatment and a shorter overall survival, posed the logical question of whether the molecule is directly involved in determining a worse clinical outcome or whether it is simply an epiphenomenon of other events. 4 A genome-wide signature of the events controlled by the CD38 pathway clearly pointed to the activation of motility programs as the main characterizing element. 5 Our hypothesis is that CD38 acts as a facilitator of the homing process of CLL cells, by actively guiding them to growth-favorable niches, mainly located in lymphoid organs. 6 To corroborate the involvement of CD38 in CLL trafficking, the homing process was dissected into distinct events and the role of the molecule examined in each of them separately. Previous evidence indicates that CD38 enhances CXCL12 sensitivity, 7 as well as CD49d-mediated adhesion, 8 suggesting that chemotaxis and adhesion can be modulated by CD38 expression. The question behind the present work is whether degradation of the extracellular matrix, the final step in the homing cascade, is also differentially active in CD38 þ -vs CD38 À -CLL patients. To answer this question, the expression and activity of MMP-9 was analyzed by gelatin zymography in a cohort of patients (n ¼ 55, Supplementary Table 1) . A marked heterogeneity in the constitutive expression and function of MMP-9 was highlighted (Figure 1a) . Patients expressing CD38 on more than 20% of the clone were endowed with significantly higher constitutive MMP-9 activity (P ¼ 0.004; Figure 1b 
